Skip to Main content Skip to Navigation
New interface
Journal articles

Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis

Abstract : Objective: To investigate the relationship of clinical response of Juvenile Idiopathic Arthritis (JIA) to etanercept (ETN) with ETN levels, and the presence of anti-drug antibodies to ETN (ADAb). Methods: Prospective study of JIA patients under 18 years old. Clinical and pharmacological data were collected at two visits. JIA clinical inactivity and activity were assessed according to the Wallace criteria and to the Juvenile Arthritis Disease Activity Score (JADAS). ETN and ADAb serum levels assessments were determined using ELISA-based assays. Results: 126 patients were enrolled. The median duration of ETN treatment at inclusion was 569 days (range 53-2340). ADAb were undetectable (<10 ng/ml) in 171/218 (78%) samples and were > 25 ng/mL in 2/218 samples. No significant relationship between ETN concentration and the clinical inactivity status and JIA activity was found using either univariate logistic regression or multiple logistic regression analysis, adjusted on one individual descriptors, time since diagnosis, time of sampling, use of corticosteroids or methotrexate and classification of JIA. No correlation was found between the remission status and the detection of ADAb. Conclusion: This study did not demonstrate any correlation between JIA activity and circulating ETN levels in a large population of patients with JIA previously treated with ETN for at least 1.5 months. As described for adults, our study confirms that ETN is marginally immunogenic in pediatric patients. These results do not support the clinical usefulness of a monitoring of ADAb or ETN concentrations for the management of this group of JIA patients if they fail to achieve clinical inactive disease. (C) 2018 Elsevier Inc. All rights reserved.
Document type :
Journal articles
Complete list of metadata
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Monday, October 25, 2021 - 8:59:21 AM
Last modification on : Thursday, October 20, 2022 - 3:10:07 PM
Long-term archiving on: : Wednesday, January 26, 2022 - 6:49:38 PM


Files produced by the author(s)


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Brigitte Bader-Meunier, Roman Krzysiek, Irene Lemelle, Christine Pajot, Aurelia Carbasse, et al.. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism, 2019, 48 (6), pp.1014-1018. ⟨10.1016/j.semarthrit.2018.09.002⟩. ⟨hal-03295376⟩



Record views


Files downloads